R. J. Slack, V. J. Barrett, V. S. Morrison, R. G. Sturton, A. J. Emmons, et al., “In Vitro Pharmacological Characterization of Vilanterol, a Novel Long-Acting β2 Adrenoceptor Agonist with 24-Hour Duration of Action,” Journal of Pharmacology and Experimental Therapeutics, Vol. 344, No. 1, 2013, pp. 218-230.
http://dx.doi.org/10.1124/jpet.112.198481

has been cited by the following article:

• TITLE: Evidence for a Non-β2-Adrenoceptor Binding Site in Human Lung Tissue for a Subset of β2-Adrenoceptor Agonists

  AUTHORS: Robert J. Slack

  KEYWORDS: β2-Adrenoceptor; Radioligand Binding; Human Lung; Tissue Binding Site

  JOURNAL NAME: Pharmacology & Pharmacy, Vol.5 No.1, January 9, 2014

  ABSTRACT: The aim of this study was to compare the binding profile of a range of β2-adrenoceptor (β2-AR) agonists and antagonists in human lung tissue. Radioligand saturation and competition binding experiments were performed by filtration with a β2-AR antagonist ([3H]propranolol) or agonist ([3H]vilanterol) radioligand and membrane fragments generated from lung parenchyma in the presence of 100 μM guanosine 5’-[β,γ-imido]triphosphate (Gpp(NH)p). In membranes prepared from human lung parenchyma, carmoterol, formoterol, ICI118551, propranolol and salbutamol resulted in inhibition of [3H]vilanterol binding to levels that were significantly different from indacaterol, salmeterol and vilanterol (ANOVA, Bonferroni post-test, P 3H]vilanterol binding to levels that were not significantly different from vilanterol (ANOVA, Bonferroni post-test, P > 0.05). Indacaterol, salmeterol and vilanterol resulted in full inhibition of [3H]propranolol binding to levels not significantly different from ICI118551 (ANOVA, Bonferroni post-test, P > 0.05). Indacaterol, salmeterol and vilanterol bind to an additional site in human lung parenchyma membranes that is distinct from the β2-AR.